These previous findings suggest that BF mediates its antitumor effects against HCC through dual inhibition of EGFR activation and subsequent attenuation of downstream RAS-RAF-MEK-ERK signaling cascade activation. Here, RAF1 is linked to hepatocellular carcinoma.